Gov. Kay Ivey signs controversial Alabama hemp regulation into law
Gov. Kay Ivey Wednesday signed a controversial bill aimed at regulating consumable hemp products into law.
HB 445, sponsored by Rep. Andy Whitt, R-Harvest, faced strong opposition from the hemp industry, which claims the bill overregulates federally legal products, and the Alabama Policy Institute, a conservative think tank, which argued it did not regulate the products enough.
Gina Maiola, a spokeswoman for Ivey, confirmed that the governor had signed the bill in a text message on Wednesday, but did not provide further comment.
Whitt said after the governor's signature that it was 'an easy bill' for him to sponsor but 'a hard bill to pass.'
'It was hard because I took shots from both sides,' he said, saying that it was difficult to listen to the 'stretches of truth,' such as claims from API that it would legalize recreational marijuana or from the industry that it's a 'complete ban.'
'It is putting guardrails on an unregulated and unlicensed product in the state of Alabama that's preying on our youth,' Whitt said.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Messages seeking comment were left with API and Molly Cole, a lobbyist for the Alabama Hemp and Vape Association, who indicated that litigation was being considered.
The legislation will require testing and labeling for all consumable hemp products and caps at 10 milligrams per individually wrapped product and 40 milligrams per package. It will require the Alcoholic Beverage Control (ABC) Board to license retailers of these products, restrict retail establishments selling hemp products and impose an excise tax on consumable hemp products.
The bill also prohibits sales to minors. It bans smokable hemp products and imposes restrictions on online sales and direct delivery.
Whitt maintained that his efforts is aimed at reducing youth access to these products, saying that the industry has operated largely unchecked.
Representatives of the hemp industry said the bill's language was vague and have suggested that litigation will follow.
Lawmakers, business owners, patients and lobbyists have also expressed uncertainty about the legislation. Whitt said that the bill also bans hemp-derived vapor products, but that is not clearly defined in the bill.
It's not clear if the bill would ban CBD, a non-psychoactive cannabinoid found in hemp. The bill explicitly bans smokable hemp products and certain psychoactive cannabinoids but defines 'consumable hemp product' broadly as any finished product intended for human or animal consumption that contains any part of the hemp plant or its derivatives.
According to the bill, 'any smokeable hemp product' not limited to 'plant product or raw hemp material that is marketed to consumers as hemp cigarettes, hemp cigars, hemp joints, hemp buds, hemp flowers, hemp leaves, ground hemp flowers, or any variation of these terms to include any product that contains a cannabinoid, whether psychoactive or not.'
Whitt said that the legislation provides an opportunity for hemp business leaders to 'pivot into the products that that are approved here in Alabama that can truly help Alabama citizens again.'
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Coffee Prices Rise on Frost Threats in Brazil
September arabica coffee (KCU25) today is up +3.10 (+1.06%), and September ICE robusta coffee (RMU25) is up +67 (+2.10%). Coffee prices today erased early losses and moved higher on concern about frost in Brazil. Meteorologist Climatempo forecasted today that a cold front will advance through Brazil's coffee-growing regions later this week, potentially bringing crop-damaging frost to the area. More News from Barchart Brazil Coffee Harvest Pressures Slam Coffee Prices Brazil Coffee Harvest Pressures Hammer Prices Cocoa Prices Rally as the Pace of Ivory Coast Cocoa Exports Slows Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Coffee prices today initially moved lower, with arabica posting a 1-week low, Sep robusta posting a contract low, and nearest-futures (N25) robusta posting a 1.25-year low. Coffee harvest pressures from Brazil are weighing on coffee prices. Last Friday, Safras & Mercado reported that Brazil's overall 2025/26 coffee harvest was 77% complete as of July 16, ahead of the comparable level of 74% last year and the 5-year average of 69%. The breakdown showed that 93% of the robusta harvest and 67% of the arabica harvest were complete as of July 9. In related news, Brazil's Cooxupe coffee co-op announced today that its harvest among its members was 59% complete as of July 18. Cooxupe is Brazil's largest coffee cooperative and Brazil's largest exporter group. Robusta coffee prices are also under pressure from an increase in ICE-monitored inventories as robusta coffee inventories today rose to an 11.5-month high of 6,401 lots. Conversely, ICE-monitored arabica coffee inventories fell to a 3-month low of 811,024 bags on Monday. An excessive short position by funds in robusta coffee could exacerbate any short-covering rally in robusta coffee futures. ICE Futures Europe reported last Friday that funds boosted their net-short positions in ICE robusta futures by 1,163 to 1,294 short positions in the week ended July 15, the most in two years. Excessive dryness in Brazil is a supportive factor for coffee prices. Somar Meteorologia reported Monday that Brazil's largest arabica coffee-growing area, Minas Gerais, received no rain during the week ended July 19. Smaller coffee exports from Brazil are positive for prices after Cecafe reported last Wednesday that Brazil's total Jun green coffee exports fell -31% y/y to 2.3 million bags, with arabica exports down -27% y/y to 1.8 million bags and robusta exports down -42% y/y to 476,334 bags. Arabica coffee prices received support from President Trump's recent announcement that he would impose 50% tariffs on US imports from Brazil, effective August 1. That threat caused concern that coffee supplies could be disrupted from Brazil, the world's largest producer of arabica coffee. Coffee prices have retreated over the past two months on the outlook for abundant coffee supplies. On June 25, the USDA's Foreign Agricultural Service (FAS) forecasted that Brazil's 2025/26 coffee production will increase by +0.5% y/y to 65 million bags and that Vietnam's 2025/26 coffee output will rise by 6.9% y/y to a 4-year high of 31 million bags. Brazil is the world's largest producer of arabica coffee, and Vietnam is the world's largest producer of robusta coffee. Due to drought, Vietnam's coffee production in the 2023/24 crop year decreased by -20% y/y to 1.472 MMT, the smallest crop in four years. Also, Vietnam's General Statistics Office reported that 2024 Vietnam coffee exports fell by -17.1% y/y to 1.35 MMT. Additionally, the Vietnam Coffee and Cocoa Association reduced its 2024/25 Vietnam coffee production estimate to 26.5 million bags on March 12, down from a December estimate of 28 million bags. By contrast, the Vietnam National Statistics Office reported on July 7 that Vietnam's Jan-Jun 2025 coffee exports were up +4.1% y/y to 943,000 MT. The USDA's biannual report, released on June 25, was bearish for coffee prices. The USDA's Foreign Agriculture Service (FAS) projected that world coffee production in 2025/26 will increase by +2.5% y/y to a record 178.68 million bags, with a -1.7% decrease in arabica production to 97.022 million bags and a +7.9% increase in robusta production to 81.658 million bags. The USDA's FAS forecasts that 2025/26 ending stocks will climb by +4.9% to 22.819 million bags from 21.752 million bags in 2024/25. For the 2025/26 marketing year, Volcafe projects a global 2025/26 arabica coffee deficit of -8.5 million bags, wider than the -5.5 million bag deficit for 2024/25 and the fifth consecutive year of deficits. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
an hour ago
- Fox News
Chinese citizen admits stealing US trade secrets for next-generation national security tech
A dual U.S.-Chinese citizen formerly employed as an engineer at a Southern California company has admitted to stealing U.S. trade secrets for next-generation national security technology. Though Chenguang Gong, 59, of San Jose, pleaded guilty to one count of theft of trade secrets, he remains free on a $1.75 million bond, according to the Justice Department. U.S. District Judge John F. Walter scheduled sentencing for Sept. 29. Prosecutors said Gong faces a statutory maximum penalty of 10 years in prison. According to his plea agreement, Gong transferred more than 3,600 files from a Los Angeles-area research and development company where he worked, to personal storage devices during his brief tenure with the company last year. Federal prosecutors said the files Gong transferred include blueprints for sophisticated infrared sensors designed for use in space-based systems to detect nuclear missile launches and track ballistic and hypersonic missiles. Other files were said to have included blueprints for sensors designed to enable U.S. military aircraft to detect incoming, heat-seeking missiles and take countermeasures, including by jamming the missiles' infrared tracking ability. "These files describe the methods, designs, techniques, processes, specifications, testing, and manufacture of these technologies and would be extremely damaging economically if obtained by the Victim Company's competitors, and would be dangerous to U.S. national security if obtained by international actors," the complaint says. The "intended economic loss" from Gong's criminal conduct exceeds $3.5 million, according to the plea agreement. Court documents note that much of the Malibu-based company's work is funded through contracts with the U.S. Department of Defense and other U.S. government contractors. Gong was hired by the company in January 2023 as an application-specific integrated circuit design manager responsible for the design, development and verification of its infrared sensors. From approximately March 30 that year until his termination on April 26, 2023, Gong allegedly transferred thousands of files from his work laptop to three personal storage devices. That included more than 1,800 files after he had accepted a job at one of the company's main competitors, prosecutors said. Prosecutors said many of the files Gong transferred contained proprietary and trade-secret information related to the development and design of a readout integrated circuit that allows space-based systems to detect missile launches and track ballistic and hypersonic missiles and a readout integrated circuit that allows aircraft to track incoming threats in low-visibility environments. Gong also allegedly transferred files containing trade secrets relating to the development of "next generation" sensors capable of detecting low-observable targets while demonstrating increased survivability in space, as well as the blueprints for the mechanical assemblies used to house and cryogenically cool the company's sensors. That information was among the company's most important trade secrets and is worth hundreds of millions of dollars, according to the DOJ. Many of the files had warnings in bold letters that the information was proprietary, export-controlled and for "official use only." The FBI executed a search warrant on May 8, 2023 at Gong's temporary residence in Thousand Oaks, California, and also searched his vehicle and his person. Law enforcement recovered multiple digital devices belonging to Gong, some of which contained the company's propriety files. The complaint says the FBI, however, did not locate two hard drives Gong used to exfiltrate the company's trade secret and proprietary information, "and the whereabouts of those drives to date remains unknown." Prosecutors said Gong repeatedly denied processing those hard drives or knowing where they were located in May 2023 interviews with the FBI. Gong was arrested on federal charges on Feb. 7, 2024, but was later released on bond. Court documents say Gong first entered the United States in or around 1993 and became a U.S. citizen in 2011. His resume states that he earned a Master of Science Degree in Electrical Engineering from Clemson University and completed some PhD work at Stanford University, according to the complaint. Law enforcement also said Gong applied to "Talent Programs" administered by the People's Republic of China while he was employed at several major technology companies in the U.S. between approximately 2014 and 2022. While employed at a U.S. information technology company headquartered in Dallas, Gong in 2014 sent a business proposal to a contact at a high-tech research institute in China focused on both military and civilian products, prosecutors said. In the proposal, Gong described a plan to produce high-performance analog-to-digital converters like those produced by his employer. In another "Talent Program" application from September 2020, prosecutors said, Gong proposed to develop "low light/night vision" image sensors for use in military night vision goggles and civilian applications. Gong's proposal included a video presentation that contained the model number of a sensor developed by an international defense, aerospace, and security company where Gong worked from 2015 to 2019, according to the DOJ. Authorities said Gong traveled to China several times to seek "Talent Program" funding in order to develop sophisticated analog-to-digital converters. The Justice Department cited a 2019 email translated from Chinese in which Gong remarked that he "took a risk" by traveling to China to participate in the Talent Programs because he worked for "an American military industry company" and thought he could "do something" to contribute to China's "high-end military integrated circuits."
Yahoo
4 hours ago
- Yahoo
Pharmaceutical Excipients Market worth $14.9 billion by 2030 with 6.1% CAGR
DELRAY BEACH, Fla., July 22, 2025 /PRNewswire/ -- The global Pharmaceutical Excipients Market, valued at US$10.5 billion in 2024 stood at US$11.0 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$14.9 billion by the end of the period. This is mainly due to factors such as growing focus on patient-centric drug formulations, increasing demand for generic drugs and pharmaceutical products, increased R&D Investments for developing novel excipients, and strategic collaborations and partnerships with pharmaceutical companies for customized excipient solutions. However, the growing high investments, development costs, and regulatory stringency are predicted to restrain the market growth. Download PDF Brochure: Browse in-depth TOC on "Pharmaceutical Excipients Market" 550 - Tables 60 - Figures515 - Pages By product, the global pharmaceutical excipients market is segmented by product type into three main categories: organic chemicals, inorganic chemicals, and other chemicals. Among these, organic chemicals comprise compounds primarily made up of carbon atoms bonded with other elements through covalent bonds. These substances are commonly used in pharmaceutical formulations due to their favorable chemical properties and compatibility with active pharmaceutical ingredients (APIs). One of the key advantages of organic chemicals is their generally non-toxic nature, making them safer for drug development and manufacturing. This characteristic is anticipated to significantly contribute to the growth of the organic chemicals segment within the excipients market. As the pharmaceutical industry continues to expand and innovate, the demand for safe and effective excipients is expected to rise. Consequently, the organic chemicals segment is likely to play a crucial role in propelling the overall pharmaceutical excipients market forward during the forecast period. The increasing focus on patient safety, regulatory compliance, and formulation efficiency further strengthens the market outlook for organic excipients. As a result, organic chemicals are positioned to remain a dominant and growing category in the global pharmaceutical excipients landscape over the coming years. By functionalities, the lubricants & glidants segment is expected to register the fastest growth rate in the pharmaceutical excipients market during the forecast period. This growth is largely driven by their critical role in improving manufacturing efficiency. Lubricants and glidants are essential in solid dosage formulations, particularly tablets and capsules, as they help reduce interparticle friction and minimize cohesion among powder particles. By enhancing powder flow properties, these excipients facilitate smoother processing during tablet compression and encapsulation, leading to more consistent product quality and reduced production downtime. In high-speed manufacturing environments, where precision and efficiency are paramount, lubricants and glidants significantly decrease the risk of mechanical issues such as sticking, picking, or clogging equipment. Furthermore, the demand for scalable and cost-effective pharmaceutical production processes continues to rise, especially with the increasing global need for solid oral medications. These factors collectively contribute to the growing importance of lubricants and glidants in formulation development, making them a key segment with strong future potential in the evolving pharmaceutical excipients landscape. By geography, the market for pharmaceutical excipients is divided into six segments: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Asia Pacific region is expected to experience the fastest growth in the pharmaceutical excipients market over the forecast period. This expansion is primarily fueled by the rapid development of pharmaceutical manufacturing capabilities, advancements in research and development infrastructure, and increasing regulatory harmonization across key countries in the region. China, India, and South Korea are making substantial investments in domestic pharmaceutical production to meet local and global demand. The growing availability of skilled professionals and improvements in technical education have supported high-quality drug formulation. The surge in chronic and infectious diseases, combined with the increasing penetration of health insurance and improved access to healthcare services, is driving the consumption of pharmaceutical products. Strategic collaborations between regional firms and global pharmaceutical players further boost innovation and market growth. These factors collectively position Asia Pacific as a major hub for future growth in the global pharmaceutical excipients market. Request Sample Pages : Key players in the pharmaceutical excipients market include International Flavors & Fragrances Inc. (US), Ashland Inc. (US), Evonik Industries AG (Germany), BASF SE (Germany), Kerry Group plc (Ireland), Roquette Frères (France), MERCK KGaA (Germany), Associated British Foods plc (UK), ADM (US), Wacker Chemie AG (Germany), Air Liquide (France), DOW (US), Berkshire Hathaway Inc. (US), Colorcon (US), DFE PHARMA (Germany), Actylis (US), Croda International Plc(UK), Chemie Trade(India), Gattefossé (France), JRS Pharma(US), and Shin-Etsu Chemical Co., Ltd. (Japan). International Flavors & Fragrances Inc. (IFF): International Flavors & Fragrances Inc. (IFF) is a prominent entity within the pharmaceutical excipients market and is a leading manufacturer of flavors, fragrances, and specialty ingredients used across various industries, such as pharmaceuticals, food, beverages, and personal care. The company operates through four key segments: Nourish, Health & Biosciences, Scent, and Pharma Solutions. In 2024, IFF maintained a strong position in the pharmaceutical excipients market, supported by a broad and diverse product portfolio. Its extensive global presence spans over 45 countries, enabling wide market access. IFF places a high priority on innovation and research, investing significantly in R&D to strengthen its product offerings and meet evolving industry demands. This strategic focus reinforces its leadership in the pharmaceutical ingredients industry. Archer Daniels Midland (ADM) Archer Daniels Midland (ADM) (US) solidified its status as a significant player in the pharmaceutical excipients market, driven by its diversified product portfolio, high-quality standards, and strategic investments. ADM supplies a broad range of pharmaceutical-grade excipients such as ethanol, sorbitol, dextrose, starches, citric acid, and various plant-derived oils, all of which are compliant with global pharmacopeia standards (USP/NF, EP, JP). These excipients are widely used in oral solid dosage forms, liquid formulations, and topical drugs. ADM's ability to consistently meet stringent regulatory and quality standards, including ISO-9001, IPEC-GMP, FDA-audited facilities, and RSPO-certified ingredients, makes it a preferred supplier among pharmaceutical manufacturers globally. Strategically, ADM continues to invest in expanding its pharmaceutical and wellness-focused capabilities, including its facility in Valencia, Spain, which was expanded in 2022 to boost the production of probiotics and postbiotics, an area that is gaining relevance in drug delivery systems. For more information, Inquire Now! Related Reports: Active Pharmaceutical Ingredient Market High Potency APIs Market Pharmaceutical Drug Delivery Market Synthetic Biology Market Pharmaceutical Contract Manufacturing Market Get access to the latest updates on Pharmaceutical Excipients Companies and Pharmaceutical Excipients Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan SalgarkarMarketsandMarkets™INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content to download multimedia: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
